Saturday 17 October 2026
Export EBS’s income statement to Excel — free account
Emergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.
6.38
0.80
−11.14%
Follow EBS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
6.26 | 13.01 | 0.00 | 0.00 |
P/S ratio |
0.59 | 0.89 | 0.64 | 0.56 | |
P/FCF ratio |
11.76 | 3.39 | 3.18 | 5.02 | |
P/Operating CF |
(204.01) | 8.51 | (12.74) | 7.71 | |
P/B ratio |
0.81 | 1.27 | 0.82 | 1.27 | |
Price to Tangible BV |
3.62 | 7.68 | 8.17 | 5.43 | |
EV/Sales |
1.12 | 1.38 | 1.25 | 1.13 | |
EV/EBITDA |
3.91 | 4.98 | 5.15 | 23.69 | |
EV/Operating CF |
67.99 | 6.01 | 5.70 | 8.95 | |
EV/FCF |
22.15 | 5.26 | 6.23 | 10.15 | |
Quick Ratio |
2.92 | 2.22 | 1.90 | 2.69 | |
Current Ratio |
5.76 | 5.01 | 4.29 | 5.42 | |
Net Debt/EBITDA |
4.04 | (201.67) | 11.51 | (4.43) | |
Debt/Assets |
45.39% | 43.39% | 43.44% | 52.10% | |
Debt/Equity |
1.14 | 1.09 | 1.10 | 1.70 | |
Asset Turnover |
0.54 | 0.55 | 0.49 | 0.61 | |
Operating CF/Net income |
(0.04) | (1.42) | (4.97) | (0.31) | |
Capex/Depreciation |
(0.13) | (0.15) | (0.09) | (0.07) | |
Interest Coverage |
5.03 | (1.90) | 0.95 | (12.51) | |
Research and Development Expense of Revenue |
5.84% | 8.14% | 6.73% | 3.93% | |
Selling, General and Administrative Expense of Revenue |
16.83% | 34.36% | 29.85% | 19.04% | |
Intangible Assets out of Total Assets |
0.31 | 0.33 | 0.36 | 0.23 | |
Share Based Compensation of Revenue |
2.08% | 3.56% | 1.22% | 2.94% | |
Graham Net Nets |
(0.20) | (0.20) | (0.37) | (0.25) | |
Graham Number |
18.64 | 14.45 | 0.00 | 0.00 | |
Earnings Yield |
15.99% | 7.69% | (2.05%) | (41.05%) | |
Free Cash Flow Yield |
8.50% | 29.49% | 31.46% | 19.91% | |
Revenue per Share |
4.34 | 2.78 | 3.01 | 4.54 | |
Operating CF per Share |
(0.04) | 1.45 | (0.65) | 1.09 | |
Capex per Share |
(0.06) | (0.07) | (0.05) | (0.04) | |
Free Cash Flow per Share |
(0.11) | 1.38 | (0.70) | 1.05 | |
Cash per Share |
4.68 | 3.91 | 3.11 | 2.73 | |
Shareholders Equity per Share |
10.95 | 9.77 | 10.08 | 6.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.95 | 9.77 | 10.08 | 6.62 | |
Free Cash Flow |
(5.70) | 73.80 | (36.20) | 54.20 | |
Working Capital |
650.40 | 530.30 | 488.90 | 543.20 | |
Capital Expenditures |
(3.40) | (3.90) | (2.40) | (1.90) | |
Net Current Asset Value |
(91.60) | (133.50) | (159.70) | (109.40) | |
EV/EBIT |
7.46 | 10.24 | 13.90 | 0.00 | |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.01 | |
Price to Operating Income |
3.96 | 6.61 | 7.10 | 0.00 | |
| Other line items | |||||
Average Receivables |
135.40 | 119.35 | 162.65 | 134.90 | |
Average Payables |
69.75 | 58.25 | 48.80 | 56.95 | |
Average Inventory |
339.50 | 327.55 | 320.80 | 321.10 | |
Average Assets |
1,469.40 | 1,354.15 | 1,373.25 | 1,266.95 | |
Average Common Equity |
545.45 | 502.70 | 537.90 | 438.80 |
Columns are period end dates